ANI Pharmaceuticals Inc. (NASDAQ:ANIP) and Aldeyra Therapeutics Inc. (NASDAQ:ALDX) compete with each other in the Biotechnology sector. We will analyze and compare their institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals Inc.	201.58M	4.09	15.34M	1.18	54.82
Aldeyra Therapeutics Inc.	N/A	0.00	38.89M	-1.77	0.00

Table 1 demonstrates ANI Pharmaceuticals Inc. and Aldeyra Therapeutics Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 provides ANI Pharmaceuticals Inc. and Aldeyra Therapeutics Inc.’s net margins, return on assets and return on equity.

	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals Inc.	7.61%	0.1%	0%
Aldeyra Therapeutics Inc.	0.00%	-99.8%	-85.2%

Volatility & Risk

ANI Pharmaceuticals Inc.’s 2.41 beta indicates that its volatility is 141.00% more volatile than that of S&P 500. In other hand, Aldeyra Therapeutics Inc. has beta of 0.79 which is 21.00% less volatile than S&P 500.

Liquidity

The Current Ratio and Quick Ratio of ANI Pharmaceuticals Inc. are 3.3 and 2.5 respectively. Its competitor Aldeyra Therapeutics Inc.’s Current Ratio is 4.8 and its Quick Ratio is 4.8. Aldeyra Therapeutics Inc. can pay off short and long-term obligations better than ANI Pharmaceuticals Inc.

Analyst Recommendations

Ratings and Recommendations for ANI Pharmaceuticals Inc. and Aldeyra Therapeutics Inc. can be find in next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
ANI Pharmaceuticals Inc.	0	0	3	3.00
Aldeyra Therapeutics Inc.	0	0	2	3.00

ANI Pharmaceuticals Inc. has a consensus price target of $75.67, and a 8.82% upside potential. On the other hand, Aldeyra Therapeutics Inc.’s potential upside is 237.21% and its average price target is $29. The information presented earlier suggests that Aldeyra Therapeutics Inc. looks more robust than ANI Pharmaceuticals Inc. as far as analyst belief.

Institutional and Insider Ownership

Roughly 81.8% of ANI Pharmaceuticals Inc. shares are held by institutional investors while 76.1% of Aldeyra Therapeutics Inc. are owned by institutional investors. 2.1% are ANI Pharmaceuticals Inc.’s share held by insiders. On the other hand, insiders held about 0.94% of Aldeyra Therapeutics Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
ANI Pharmaceuticals Inc.	6.15%	20.06%	15.86%	11.7%	5.74%	43.31%
Aldeyra Therapeutics Inc.	4.71%	-9.19%	-11.11%	3.23%	-4.19%	-3.61%

For the past year ANI Pharmaceuticals Inc. had bullish trend while Aldeyra Therapeutics Inc. had bearish trend.

Summary

ANI Pharmaceuticals Inc. beats Aldeyra Therapeutics Inc. on 9 of the 11 factors.

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and Hydrocortisone Enema and Cortenema to treat ulcerative colitis. It also provides Hydrocortisone Rectal Cream to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Lithium Carbonate ER and Lithobid for bipolar disorder; Mesalamine Enema to treat distal ulcerative colitis, proctosigmoiditis, or proctitis; Methazolamide to treat ocular conditions; and Metoclopramide and Reglan to treat gastroesophageal reflux. In addition, the company offers Nilutamide to treat metastatic prostate cancer; Nimodipine that reduces the ischemic deficits in patients with subarachnoid hemorrhage; Opium Tincture to treat diarrhea; Oxycodone capsules and oral solution for pain; Propafenone to treat arrhythmia; Propranolol ER and Inderal LA for managing hypertension in patients with angina pectoris; and Vancomycin and Vancocin for use in treating C. difficile-associated diarrhea and enterocolitis. Further, it provides contract manufacturing services for other pharmaceutical companies. The company markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota.

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.